ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063 on ClinicalTrials.gov · last registry update 2026-10-16
Registered but not yet open, with 600 participants planned. Due to report 29 April 2029, alongside 14 other tracked readouts that quarter. Primary outcome, as filed: Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters. Sponsors move these dates routinely; any movement since this site started watching is listed below. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 600
- Started
- 2026-10-23
- Primary completion
- 2029-04-29 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-30 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters
Conditions studied
Obesity · Metabolic Dysfunction-associated Steatotic Liver Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.